Browse the corpus

Antihistamines remain a cornerstone of therapy for allergic and acid-related disorders, yet evolving evidence continues to reshape their clinical use. This activity provides an in-depth review of the pharmacology, therapeutic applications, and safety considerations of H1 and H2 receptor antagonists—agents widely used across multiple care settings. Participants explore current understanding of histamine receptor physiology, mechanisms of action, and distinctions between first- and second-generation antihistamines, with emphasis on clinical decision-making for allergic rhinitis, chronic urticaria, and gastroesophageal reflux disease. Learners examine updated evidence-based prescribing practices, emerging safety data, including withdrawal symptoms and cardiotoxicity, and the management of special populations such as pediatric, geriatric, and pregnant patients. The course also highlights advances in pharmacogenomics that enable personalized selection of antihistamines and reviews novel treatment options, including biologics and small molecules for refractory urticaria. Through interactive case studies, expert commentary, and interprofessional discussion, participants strengthen their competence in optimizing therapy, mitigating adverse effects, and enhancing patient education. This activity addresses key knowledge and performance gaps identified in recent clinical reviews, supporting the development of coordinated, patient-centered strategies. By completing this program, healthcare professionals are better equipped to integrate new evidence into practice, improve patient safety, and promote collaborative management of allergy and gastrointestinal disorders. Objectives: Differentiate between first-generation and second-generation H1 antihistamines, including their pharmacokinetic properties, adverse effect profiles, and appropriate clinical uses. Apply updated evidence-based guidelines for antihistamine use in allergic rhinitis, urticaria, gastroesophageal reflux disease, and peptic ulcer disease, including appropriate dosing and up-dosing strategies. Identify key safety considerations, contraindications, and monitoring requirements for antihistamine therapy, particularly in vulnerable populations such as those with hypertension or chronic diseases, pediatrics, geriatrics, and pregnant patients.

Apply updated evidence-based guidelines for antihistamine use in allergic rhinitis, urticaria, gastroesophageal reflux disease, and peptic ulcer disease, including appropriate dosing and up-dosing strategies. Identify key safety considerations, contraindications, and monitoring requirements for antihistamine therapy, particularly in vulnerable populations such as those with hypertension or chronic diseases, pediatrics, geriatrics, and pregnant patients. Implement evidence-based antihistamine therapy by applying pharmacology, clinical use, and safety principles, while examining emerging biologics, small-molecule therapies, pharmacogenomics, and interprofessional collaboration to optimize patient outcomes. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose First-generation antihistamine overdose can cause CNS depression, paradoxical excitation, respiratory failure, anticholinergic toxicity, and arrhythmias. The Centers for Disease Control and Prevention analyzed data from the State Unintentional Drug Overdose Reporting System across 43 US states and the District of Columbia to evaluate the role of antihistamines, particularly first-generation H1 antihistamines, in fatal overdoses between 2019 and 2020. Deaths involving antihistamines alone were rare (<0.1%), highlighting that synergistic toxicity with other sedatives, particularly opioids, was the major contributor to fatality. The findings showed that approximately 15% of all overdose deaths during the study period were antihistamine-positive, and about 4% were antihistamine-involved (listed as a cause of death). Diphenhydramine accounted for most cases, representing the predominant agent among first-generation H1 antihistamines detected. The co-involvement of opioids, especially illicitly manufactured fentanyls, was strikingly high, with over 80% of antihistamine-involved deaths also involving opioids. The sedative and anticholinergic properties of first-generation H1 antagonists, such as diphenhydramine, can potentiate opioid-induced respiratory depression and increase fatal overdose risk.[30] The severity of poisoning from second-generation antihistamines appears to be low among children and considerably lower than poisoning caused by first-generation antihistamines.[31] Management of Overdose Treatment of an antihistamine overdose is supportive with activated charcoal and monitoring.[32] Consult a medical toxicologist in case of a complex overdose and contact the poison control center for the latest recommendations.[33]

Second-generation antihistamines provide superior symptom control and improved safety compared to first-generation agents. Fexofenadine exhibits minimal sedation, whereas cetirizine and levocetirizine may cause mild drowsiness in some patients.[34] Rupatadine, which combines histamine and platelet-activating factor antagonist properties, is currently under review for approval in the United States.[35] The 2024 consensus guidelines support updosing of second-generation antihistamines for refractory urticaria.[36] Public Health and Over-the-Counter Misuse Increased misuse of diphenhydramine among youth, linked to social media Benadryl challenges, precipitated FDA warnings and pharmacist-led awareness campaigns.[Social Media Challenge: Encouraging Adolescents to Engage in Dangerous Over-the-Counter Drug Use] OTC availability does not equate to safety, especially for children, older, and cardiac-compromised individuals. Controversies and Emerging Areas Combination H1/H2 blockade offers limited additional benefits in refractory urticaria, except in select cases of severe disease. No proven antiviral benefit of antihistamines against COVID-19, despite early in vitro results.[37] Biologic agents and oral small molecules are transforming the management of chronic urticaria. Research Advances H4 receptor antagonists show promising anti-inflammatory activity against pruritus and atopic dermatitis but have yet to secure regulatory approval.[38] The clinical efficacy of diamine oxidase supplementation for histamine intolerance remains inconclusive. Emerging Histamine Receptors and Future Therapeutics Beyond the classical H1 and H2 receptors, research on H3 and H4 antagonists is advancing rapidly. H4 receptors, expressed on mast cells, dendritic cells, and T cells, modulate inflammatory cell chemotaxis and vascular permeability. Selective H4 antagonists reduce inflammation and vascular leakage in preclinical models of asthma and dermatitis; however, as of 2025, no H3 or H4 receptor antagonists have received clinical approval.[38] Antihistamines Beyond Allergy: Repurposing and Novel Indications

Beyond the classical H1 and H2 receptors, research on H3 and H4 antagonists is advancing rapidly. H4 receptors, expressed on mast cells, dendritic cells, and T cells, modulate inflammatory cell chemotaxis and vascular permeability. Selective H4 antagonists reduce inflammation and vascular leakage in preclinical models of asthma and dermatitis; however, as of 2025, no H3 or H4 receptor antagonists have received clinical approval.[38] Antihistamines Beyond Allergy: Repurposing and Novel Indications Recent studies demonstrate that some second-generation H1 antihistamines may modulate the tumor microenvironment, inhibit histamine-mediated immunosuppression, and reduce cancer cell proliferation.[39]. These insights open possibilities for repurposing antihistamines as adjunctive oncology therapeutics, and ongoing clinical trials are exploring these applications. Pharmacogenomics and Personalized Medicine Genetic variation in CYP450 enzymes, notably CYP2D6 and CYP3A4, as well as transporters such as ABCB1, influences the metabolism, tissue distribution, efficacy, and adverse effect profiles of antihistamines. Although pharmacogenomic testing is not yet routine, emerging evidence supports its future role in guiding personalized dosing, particularly for patients with chronic urticaria who are resistant to high-dose antihistamines.[20] Polymorphisms in the histamine H1 receptor gene also correlate with response variability. Antihistamines and COVID-19 In vitro studies indicate that certain H1 antihistamines, such as acrivastine, interfere with SARS-CoV-2 spike protein binding and viral entry by targeting H1 receptors, thereby reducing pseudoviral infection in cell and mouse models. However, current clinical trial data do not support the use of antihistamines for the treatment or prevention of COVID-19 in humans.[40] Novel Biologic and Small-Molecule Agents for Refractory Urticaria

In vitro studies indicate that certain H1 antihistamines, such as acrivastine, interfere with SARS-CoV-2 spike protein binding and viral entry by targeting H1 receptors, thereby reducing pseudoviral infection in cell and mouse models. However, current clinical trial data do not support the use of antihistamines for the treatment or prevention of COVID-19 in humans.[40] Novel Biologic and Small-Molecule Agents for Refractory Urticaria Management of chronic spontaneous urticaria has advanced with the FDA approvals of biologics, such as dupilumab, which targets the IL-4/IL-13 pathways, and remibrutinib, an oral Bruton's tyrosine kinase inhibitor that modulates mast cell function. In early clinical trials, monoclonal antibodies targeting the mast cell growth factor receptor cKIT (e.g., barzolvolimab, briquilimab) have shown promising disease-modifying activity. These developments broaden the options for patients who are antihistamine-refractory.[41] Clinical Trials and Future Directions Phase III trials are ongoing for novel biologics, histamine receptor antagonists, and therapy adjuncts targeting allergic and inflammatory conditions. Innovations in drug delivery, including nanocarriers, transdermal patches, and microneedles, aim to enhance bioavailability and adherence. The rise of biomarker-driven personalized medicine informs trial design and patient selection, optimizing outcomes.[42]

Phase III trials are ongoing for novel biologics, histamine receptor antagonists, and therapy adjuncts targeting allergic and inflammatory conditions. Innovations in drug delivery, including nanocarriers, transdermal patches, and microneedles, aim to enhance bioavailability and adherence. The rise of biomarker-driven personalized medicine informs trial design and patient selection, optimizing outcomes.[42] Effective allergy and antihistamine management relies on interprofessional collaboration. The clinician evaluates the patient, establishes the diagnosis, and selects appropriate antihistamine therapy. Advanced Practice Providers, including nurse practitioners and physician associates, conduct patient assessments, initiate or adjust therapy within protocol, and reinforce adherence. Nurses administer medications, monitor for immediate adverse reactions, provide patient counseling, and document responses in the medical record. Pharmacists ensure correct drug selection, verify dosing, identify potential drug interactions, counsel on adverse effects, and provide guidance on safe use during special conditions such as pregnancy or breastfeeding. Immunologists contribute expertise in complex or refractory allergic cases, advising on immunotherapy or advanced diagnostic testing. Patient education underpins all roles, ensuring patients understand the purpose of their medication, dosing schedules, potential adverse effects, and when to seek medical attention, thereby improving adherence and clinical outcomes. Collaborative review and decision-making ensure clinicians, pharmacists, nurses, and other professionals contribute their expertise to optimize antihistamine therapy. This approach reduces adverse effects, ensures appropriate dosing, and improves patient adherence and clinical outcomes. An interprofessional team approach and effective communication with patients and other healthcare professionals, including clinicians, advanced practice providers, pharmacists, and nurses, are crucial to minimizing potential adverse effects and enhancing patient outcomes related to antihistamine therapy.